Clinical trials: MRD
MRD
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer…
- Trial name
- NCT05536505
- Testing
- Adjuvant treatment for MRD positivity
- Where
- 16 sites in China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Multiple Myeloma
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first…
- Trial name
- NCT04513639
- Testing
- Early treatment of relapse with carfilzomib, dexamethasone, daratumumab, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
- Where
- 13 sites in Norway
- Volunteers
- 176 people
- Sponsor
- Oslo University Hospital
Acute Myeloid Leukemia
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in…
- Trial name
- NCT04086264
- Testing
- Azacitidine, IMGN632, Venetoclax
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 218 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Measurable Disease
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Measurable disease (MRD) plays an important role in the therapeutic efficacy and prognosis of acute myeloid leukemia (AML). Studies show that persistent MRD positivity after induction indicates that the patient has a higher risk…
- Trial name
- NCT05361057
- Testing
- Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Cancer
Discontinuation Study
An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have…
- Conditions
- Multiple Myeloma, Cancer, Hematologic Cancer
- Trial name
- NCT05866757
- Testing
- Discontinuation of maintenance treatment
- Where
- Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Multiple Myeloma, Newly Diagnosed
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly…
- Trial name
- CAREMM-008 (NCT07106736)
- Testing
- BCMA CAR-T, GPRC5D/CD3 BiTEs
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ALL, Recurrent, Adult
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT.
- Trial name
- NCT03109093
- Testing
- Blinatumomab
- Where
- 22 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Goethe University
Lymphoid Leukemia, Non-Hodgkin's Lymphoma
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT04155840
- Testing
- Copanlisib, Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
NSCLC
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Seagull is a phase Ⅱ study designed to investigate the efficacy and safety of MRD-guided adjuvant tislelizumab and chemotherapy vs adjuvant tislelizumab and chemotherapy in patients with resectable NSCLC
- Trial name
- Seagull (NCT05286957)
- Testing
- adjuvant tislelizumab and chemotherapy for MRD+ patients, adjuvant chemotherapy for MRD- patients
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Colorectal Cancer
MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
The aim of this clinical trial is to test whether minimal residual disease (MRD) status detected by circulating tumor DNA (ctDNA) could be used to guide precision therapy of post-surgery in colon cancer.
- Trial name
- MIRROR (NCT06204484)
- Testing
- CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Sun Yat-sen University
Acute Myeloid Leukemia, Pediatric AML
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at…
- Trial name
- NCT07059975
- Testing
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
B-ALL
The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation
To explore the efficacy and safety ofblinatumomab± TKI in B-ALL patients aged ≥ 14 years with NGS-MRD relapse (sensitivity: 10-6) after auto/allo HSCT, and to observe the disease-free survival (DFS), recurrence rate and toxicity…
- Trial name
- NCT06504186
- Testing
- Blinatumomab
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Risk Stratification and MRD-driven Maintenance for MM After ASCT
This study evaluates the maintenance strategy based on risk stratification and MRD status after stem cell transplantation. This is a single-arm, multicenter, prospective study.
- Trial name
- NCT06697483
- Testing
- Daratumumab, Lenalidomide
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital